Corteva, Inc. (NYSE:CTVA) has been in the news after the company completed the spin-off of its seed and genetics business into Vylor Inc. (NYSE:VYLR) on Thursday.

Corteva is now a pure-play global crop protection company. The company said the business increased revenue by more than $1 billion between 2020 and 2025.

Corteva also highlighted an $11 billion crop protection pipeline and expects to launch 12 new active ingredients over the next decade, including five biological products.

During its investor day last month, Corteva said it expects net sales to rise from approximately $7.8 billion in 2026 to between $8.4 billion and $8.7 billion by 2029, implying a roughly 3% compound annual growth rate at the midpoint.

Standalone operating EBITDA is expected to increase from approximately $1.3 billion in 2026 to $1.45 billion-$1.65 billion by 2029, representing a 6% CAGR at the midpoint. Standalone EBITDA margins are expected to exceed 18% by 2029.

Also, Corteva expects $300 million in gross productivity benefits from 2027-2029 and more than $200 million in net cost improvements after inflation and tariff offsets. Most remaining inflation and tariff pressure is expected in 2027.

The company also said its seed-treatment portfolio has grown to about $500 million from roughly $400 million before the separation.

Vylor's Operations & Guidance

Vylor operates as an advanced seed and genetics company. Its $19 billion technology pipeline includes 12 major platform launches across corn, soybeans and wheat over the next decade.

The company plans seven new corn technology platforms starting in 2028, including a yield and yield-stability trait that delivered an average three-bushel-per-acre gain in trials, with increases of up to 10 bushels. It is also developing gene-edited, multi-disease-resistant corn.

Vylor plans four new soybean platforms by 2035, including a proprietary Latin American technology offering broad-spectrum insect control, strong yields and licensing opportunities. Its Xpedite hybrid wheat system is expected to launch in North America in late 2027, with trials showing strong yields and resilience to disease and drought.

Through Vylor One, licensing income is expected to exceed $500 million in 2027, $1 billion by 2035 and approach $2 billion by 2040. Vylor targets 2029 net sales of $11.2 billion-$11.9 billion and operating EBITDA of $3.3 billion-$3.7 billion.

Price Action: Vylor shares were up 2.56% at $70.01 and Corteva shares were down 5.09% at $11.93 at the time of publication on Friday, according to market data.